Aurinia Pharmaceuticals Inc (AUPH) News
Filter AUPH News Items
AUPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AUPH News Highlights
- For AUPH, its 30 day story count is now at 6.
- Over the past 22 days, the trend for AUPH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about AUPH are ADMA, LYRA and ALPN.
Latest AUPH News From Around the Web
Below are the latest news stories about AURINIA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate AUPH as an investment opportunity.
Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year. |
Aurinia Submits IND Application to US Food & Drug Administration for AUR 200ROCKVILLE, Md. & EDMONTON, Alberta, December 20, 2023--Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 |
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey MedicalAurinia Pharmaceuticals, Alpine Immune Sciences, Lyra Therapeutics, Harpoon Therapeutics and Journey Medical are part of the Zacks Industry Outlook article. |
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New YearInnovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio. |
This Small Pharma Could Be Targeted, But Would Be Fine Alone, TooAt the end of November, AbbVie bought ImmunoGen, Inc. for $10 billion in cash. The purchase of ImmunoGen caused that stock to soar some 90%. Back to the covered call idea on a small biopharma Aurinia Pharmaceuticals, which currently trades just under nine bucks a share. |
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?Here is how Adma Biologics (ADMA) and Aurinia Pharmaceuticals (AUPH) have performed compared to their sector so far this year. |
Investors in Aurinia Pharmaceuticals (NASDAQ:AUPH) have seen favorable returns of 78% over the past yearPassive investing in index funds can generate returns that roughly match the overall market. But one can do better than... |
Can Aurinia (AUPH) Climb 46.13% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 46.1% in Aurinia (AUPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Is Aurinia Pharmaceuticals (AUPH) Stock Outpacing Its Medical Peers This Year?Here is how Aurinia Pharmaceuticals (AUPH) and Adma Biologics (ADMA) have performed compared to their sector so far this year. |
Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in JapanROCKVILLE, Md. & EDMONTON, Alberta, November 13, 2023--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan |